Live Attenuated Influenza Vaccine As a Nasal Model for Influenza Infection
NCT04164212
Recruiting
The purpose of this study is to develop a nasal model for influenza infection using the live attenuated influenza vaccine (LAIV). The investigators will administer LAIV to healthy adult volunteers in order to simulate influenza infection, and obtain nasal specimens to measure influenza virus and inflammatory/immune responses. In a subset of participants, cystic fibrosis transmembrane conductance regulator (CFTR) function will also be evaluated via measurement of nasal potential difference (NPD)
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
10/30/2024
Locations: UAB Lung Health Center, Birmingham, Alabama
Conditions: Influenza
Register for Updates
Fever After Simultaneous Versus Sequential Vaccination in Young Children
NCT03165981
Completed
A prospective, randomized open-label clinical trial that will be conducted during the 2017-2018 influenza season. During the 2017-2018 season, approximately 280 children will be enrolled at Duke University Medical Center and Kaiser Permanente Northern California. Eligible children will be randomized to receive simultaneous or sequentially administered US licensed PCV13, US-licensed DTaP vaccine, and US-licensed inactivated influenza vaccine (IIV). Children in the simultaneous group will receive... Read More
Gender:
ALL
Ages:
Between 12 months and 16 months
Trial Updated:
10/30/2024
Locations: Kaiser Permanente Northern California, Oakland, California +2 locations
Conditions: Fever After Vaccination, Fever, Febrile Seizure
Register for Updates
Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products
NCT00695279
Completed
This protocol (GENEFU) provides a mechanism for the 15-year followup period that the FDA requires for all participants in gene transfer protocols and assures that adequate followup can be maintained for a wide variety of participants on different individual gene therapy protocols at St. Jude Children's Research Hospital. GENEFU serves as an umbrella protocol for long-term follow-up (LTFU) for recipients of gene therapy/gene marked (GT/GM) products at St. Jude Children's Research Hospital. The F... Read More
Gender:
ALL
Ages:
All
Trial Updated:
10/29/2024
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Severe Combined Immunodeficiency, Malignancy, Hematologic, Neuroblastoma, Neoplasm, Mucopolysaccharidosis I
Register for Updates
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
NCT04060277
Active Not Recruiting
This phase II trial studies how well Triplex vaccine works in preventing cytomegalovirus (CMV) infection in patients undergoing a hematopoietic stem cell transplantation. CMV is a virus that may be carried for life and does not cause illness in most healthy individuals. However, in people whose immune systems are lowered (such as those undergoing stem cell transplantation), CMV can reproduce and cause disease and even death. The Triplex vaccine is made up of 3 small pieces of CMV deoxyribonuclei... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Register for Updates
Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines
NCT04529538
Completed
The purpose of this study is to assess the safety (primary objective), the ability to trigger the production of antibodies (immunogenicity; a secondary objective) and presence of vaccine virus in the stool (fecal shedding; a secondary objective) of two novel oral polio vaccines (nOPV), novel oral poliomyelitis vaccine type 1 (nOPV1) and novel oral poliomyelitis vaccine type 3 (nOPV3), as compared to Sabin strain monovalent oral poliomyelitis vaccine (mOPV) controls, in healthy adults.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
10/28/2024
Locations: Pharmaron CPC, Inc., Baltimore, Maryland +3 locations
Conditions: Poliomyelitis
Register for Updates
PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED
NCT06156215
Completed
The goal of this cluster randomized clinical trial is to test the efficacy of messaging interventions to increase booster vaccine uptake in adults in the emergency department(ED). The main question\[s\] and goals of this study are: * does the intervention of vaccine messaging increase booster vaccine uptake at 30 days post ED visit? * does the intervention of asking about vaccine acceptance increase booster vaccine uptake at 30 days post ED visit? * considering recent national changes to fundin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/25/2024
Locations: San Francisco General Hospital Emergency Department, San Francisco, California +6 locations
Conditions: COVID-19
Register for Updates
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)
NCT05425732
Completed
This is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of V116 compared to PCV20 (pneumococcal 20-valent conjugate vaccine (\[Prevnar 20™ / APEXXNAR™\]) in pneumococcal vaccine-naïve adults. It is hypothesized that V116 is noninferior to PCV20 for the common serotypes and superior to PCV20 for the unique serotypes as assessed by serotype specific opsonophagocytic activity (OPA) 30 days postvaccination. It is also hypothesiz... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: Central Research Associates ( Site 0067), Birmingham, Alabama +111 locations
Conditions: Pneumococcal Infection
Register for Updates
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
NCT04201873
Recruiting
This phase I trial studies the side effects and how well of pembrolizumab and a vaccine therapy (ATL-DC vaccine) work in treating patients with glioblastoma that has come back (recurrent) and can be removed by surgery (surgically accessible). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Vaccines, such as ATL-DC vaccine, may help the body build an effectiv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: Quan, Los Angeles, California
Conditions: Recurrent Glioblastoma
Register for Updates
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
NCT04904549
Completed
The purpose of this Phase III study is to assess the efficacy, safety, and immunogenicity of two CoV2 preS dTM-AS03 vaccines (monovalent and bivalent) as part of primary series vaccinations in a multi-stage approach, as well as a booster injection of a CoV2 preS dTM-AS03 vaccine, in adults 18 years of age and older. A total of approximately 21 046 participants are planned to be enrolled (5080 per study intervention group in Stage 1 and 5443 per study intervention group in Stage 2). Initial, do... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: AES - DRS - Simon Williamson Clinic, PC - Birmingham Site Number : 8400004, Birmingham, Alabama +85 locations
Conditions: COVID-19
Register for Updates
High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant
NCT02860039
Completed
This phase II randomized trial studies how well high dose flu vaccine works in treating children who have undergone done stem cell transplant. Higher dose flu vaccine may build a better immune response and may provide better protection against the flu than the standard vaccine.
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
10/10/2024
Locations: UCSF Children's Hospital, San Francisco, California +8 locations
Conditions: Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm, Influenza
Register for Updates
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US
NCT03537508
Completed
The purpose of this study was to compare the immunogenicity and describe the safety of MenACYW conjugate vaccine and MENVEO® when both are administered concomitantly with routine pediatric vaccines to healthy infants and toddlers in the US.
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
10/10/2024
Locations: Birmingham Pediatric Associates Site Number : 8400026, Birmingham, Alabama +69 locations
Conditions: Healthy Volunteers (Meningococcal Infection)
Register for Updates
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
NCT04697576
Recruiting
This phase I trial investigates the effects of influenza vaccine in treating patients with stage I-IV melanoma. While intramuscular administration of influenza vaccine provides immunization against the influenza virus, giving influenza vaccine directly into the tumor (intralesional) may decrease the size of the injected melanoma tumor, or the extent of the melanoma within the body.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
10/06/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Register for Updates